Table 1. .

Overview of 11 patients who had a lesion that had decreased in size on prebiopsy planning CT

Patient no.	Age	Gender	Location lesion	Working diagnosis before biopsy	Lesion size on previous imaginga	Lesion size on planning CTa	Days between previous imaging and planning CT	Biopsy done?	Final diagnosis	Reference standard
1	62	F	Abdomen (retroperitoneal)	Malignancy	10.1 cmb	4.7 cmb	81	No	Benign (probably haematoma)	7-month clinical and CT follow-up
2	7	M	Lung	Metastasis, infection	Numb	Numb	10	No	Benign (probably infection)	3-month clinical and radiographical follow-up
3	43	F	Lung	Malignancy, infection, inflammation	3.1 cmb	1.6 cmb	55	No	Benign (probably infection)	8-month clinical and FDG-PET/CT follow-up
4	52	M	Lung	Metastasis, infection	4.0 cmc	2.6c	57	No	Benign (probably infection)	4-month clinical and FDG-PET/CT follow-up
5	57	F	Lung	Malignancy, infection	3.9 cmc	NVb	59	No	Benign (probably infection)	7-month clinical and CT follow-up
6	81	M	Lung	Malignancy, infection	NRMc	NVb	20	No	Benign and malignant (infection and low-grade lymphoplasmacytic lymphoma)	Autopsy
7	38	M	Lung	Infection	Numc	Numc	8	No	Benign (probably infection)	6-month clinical and FDG-PET/CT follow-up
8	64	M	Lung	Malignancy	NRMa	NRMc	14	No	Unclear	Not availabled
9	79	M	Lung	Malignancy, infection	7.8 cmb	49c	42	No	Benign (probably infection)	1-month clinical and radiographical follow-up
10	69	F	Abdomen (perihepatic)	Metastasis	1.8 cmb	NRMc	46	Yes	Benign	Biopsy (no malignancy) and 49-month clinical and CT follow-up
11	60	F	Lung	Malignancy	2.8 cmb	2.3c	19	Yes	Malignant (large-cell neuroendocrine carcinoma)	Biopsy

Num: not a clear single target lesion, but numerous lung lesions that decreased in size

NV: not visible anymore

NRM: not reliably measurable

^aAxial long-axis diameter

^bOn contrast-enhanced CT

^cOn unenhanced CT

^dGround-glass lesion decreased in size, but its nature could not be determined anymore on follow-up imaging due to the administration of chemotherapy for lung adenocarcinoma at another location